Mark W. Sawicki Sells 1,367 Shares of Cryoport, Inc. (NASDAQ:CYRX) Stock

Cryoport, Inc. (NASDAQ:CYRX) insider Mark W. Sawicki sold 1,367 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $23,977.18. Following the transaction, the insider now directly owns 77,444 shares in the company, valued at $1,358,367.76. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Cryoport Stock Up 4.4 %

Shares of NASDAQ CYRX opened at $18.12 on Thursday. The stock has a market capitalization of $887.52 million, a price-to-earnings ratio of -8.24 and a beta of 1.61. Cryoport, Inc. has a 52 week low of $9.00 and a 52 week high of $24.30. The firm has a 50-day moving average price of $15.95 and a 200 day moving average price of $14.37. The company has a quick ratio of 11.16, a current ratio of 11.73 and a debt-to-equity ratio of 0.82.

Analyst Ratings Changes

Several research analysts have issued reports on CYRX shares. Stephens reissued an “equal weight” rating and set a $17.00 price objective on shares of Cryoport in a research report on Wednesday, March 13th. Needham & Company LLC lowered their target price on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Finally, UBS Group lifted their target price on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a report on Friday, March 15th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYRX. Tower Research Capital LLC TRC grew its holdings in shares of Cryoport by 228.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the company’s stock worth $36,000 after acquiring an additional 1,433 shares during the period. Quarry LP acquired a new stake in shares of Cryoport in the 2nd quarter worth approximately $40,000. State of Wyoming grew its holdings in shares of Cryoport by 42.7% in the 4th quarter. State of Wyoming now owns 3,026 shares of the company’s stock worth $53,000 after acquiring an additional 905 shares during the period. Comerica Bank acquired a new stake in shares of Cryoport in the 3rd quarter worth approximately $53,000. Finally, Natixis Investment Managers International grew its holdings in shares of Cryoport by 61.5% in the 4th quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after acquiring an additional 1,727 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.